21.01.19

Beta Thalassemia: clinical trial provides encouraging evidence for efficacy of gene therapy

Gene therapy, especially if administered early, could be an effective treatment strategy for beta thalassemia, a genetic disease that is quite common in Mediterranean countries, affecting over 7000 patients in Italy only.

From Research

14.11.18

A new ingredient to potentiate gene therapy in stem cells

A new study published by the research team led by Anna Kajaste-Rudnitski at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Milan, shows that a naturally occurring compound significantly increases the efficiency of lentiviral vector-mediated gene transfer in blood stem cells.

From Research

21.06.16

Preliminary results reporting the safety and effectiveness of gene therapy in patients with metachromatic leukodystrophy published in The Lancet

The gene therapy developed in the laboratories of the San Raffaele Telethon Institute for Gene Therapy in Milan (SR-Tiget) remains effective as a potential early treatment of metachromatic leukodystrophy (MLD).

From Research

30.05.16

Strimvelis receives European marketing authorisation to treat ADA-SCID

The European Commission has approved the first ex-vivo stem cell gene therapy to treat patients with a very rare disease of the immune system

From Telethon Foundation

16.06.14

Gene therapy: a "molecular scalpel" corrects the genes of blood stem cells

A group of researchers at the San Raffaele Telethon Institute for Gene Therapy (TIGET) in Milan was able for the first time to rewrite the DNA of human blood stem cells by editing the genome.

From Research

14.01.14

TIGEM: a centre of excellence for the south

The new premises of the Telethon Institute for Genetics and Medicine (Tigem) is set to open in the former "Olivetti area" in Pozzuoli.

From Research

09.07.13

The Hiv virus used to cure two severe genetic diseases

The AIDS virus can be used to treat two severe hereditary diseases.

From Research

24.10.12

Alliance between Fondazione Telethon and biopharmaceutical company Shire for research and development of new therapies for rare genetic diseases

Fondazione Telethon has signed an important agreement to collaborate with the international pharma company Shire plc.

From Telethon Foundation

18.10.10

A Tripartite Alliance to Cure Seven Genetic Diseases

Fondazione Telethon, Ospedale San Raffaele, and GlaxoSmithKline have entered into a strategic alliance to develop and make available innovative gene therapies for seven severe rare genetic diseases.

From Telethon Foundation

Il tuo browser non è più supportato da Microsoft, esegui l'upgrade a Microsoft Edge per visualizzare il sito.